[The role of radiotherapy in the treatment of stage I-II Hodgkin's disease in children].
The results of treatment of I-II stage Hodgkin's disease in children aged 2-14 have been studied. 5-year survival in the group of patients (34 persons) subjected only to radiotherapy was 87.3% of which 63.4% had no recurrences. The radiotherapy is found to be an adequate method for treatment of Hodgkin's disease I-IIa stage in patients over 5 with histological types of lymphocytes prevalence and of nodular sclerosis. The volume dose of radiation does not effect the results significantly and may be limited to irradiation of local zones. When radiation is used in monotherapy there appeared factors worsening the prognosis of the disease. These are: age below 5, common symptoms and/or signs of biological activity of the process, histological mixed-cellular type or the type of lymphoid exhaustion. These factors do not affect significantly the prognosis of disease for children treated with chemoradiotherapy. In the presence of unfavourable factors only chemotherapy should be used. It does not result in the increase in 5-year survival but increases significantly (up to 90.9%) the frequency of recurrency-free interval.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone
Rol' luchevoĭ terapii v lechenii limfogranulematoza I-II stadii u deteĭ.